Search

Professional Education
Alzheimer's 5 : Use of Pharmacotherapy for Patients with Major Neurocognitive Disorder
This activity includes video lectures and is the fifth in a series of courses that seek to educate clinicians on standardized screening, evaluation, and disease management of Alzheimer's disease and related dementias. This fifth course focuses on the most frequently used and FDA-approved prescription medications for Alzheimer's disease and dementias, the current research regarding its use, and guidelines for prescribing and discontinuing medication. The program will incorporate cultural values and beliefs when creating and sharing the pharmacological care plan. [1.75 AMA PRA Category 1 Credits™, 1.75 Contact Hours (ANCC)]

Professional Education
Loss Lessons: Recognition of Wernicke Encephalopathy
Wernicke encephalopathy (WE) is a syndrome commonly seen in patients with alcohol use disorder who do not take adequate thiamine. WE should be suspected in any patient with conditions that may lead to malnutrition in combination with any of the following symptoms: altered mental status ophthalmoplegia, ataxia, delirium, and hypotension. Considered a medical emergency, it must be reversed to prevent permanent deficits. This case illustrates a cascade of errors which led to permanent disability. Some practical interventions to quickly recognize and reverse the condition are offered following the case presentation, which will be helpful for gastroenterology/gastroenterologists, ophthalmology/ophthalmologists, and neurology/neurologists.

Professional Education
Module 4: Recognition, Diagnosis, and Treatment of Substance Use Disorder (Innovations and Smart Approaches in Safe Prescribing)
Learn several new concepts and innovation tips. Learn about the new CDC Guidelines about pain. This program will show how to treat pain, opioid withdrawal, and/or opioid addiction. It will show how to taper opioids and you will learn how to conduct “motivational interviewing.” You will be shown strategies for recognizing substance use disorder (SUD) and opioid use disorder (OUD). Refamiliarize yourself with screening for fentanyl. Provide valuable pharmacological and nonpharmacological resources to connect patients to treatment for addiction. Discuss individualized treatment plans that are tailored to specific patient needs when treating OUD. This module consists of four audio-filled videos. To successfully complete this course, you need to achieve a passing score of 80 percent in the post-test questions.

October 16, 2022, The Art of Medicine with Dr. Andrew Wilner
Avoiding Medical Malpractice: An Interview with David Feldman, MD, MBA
Dr. David L. Feldman, Chief Medical Officer for The Doctors Company, speaks with Andrew Wilner, MD, FACP, FAAN, Associate Professor of Neurology, The University of Tennessee Health Science Center, on ways to improve patient outcomes and prevent medical malpractice.

May 11, 2023, Inside Medical Liability Online
Postpartum Malpractice Claims: Can We Understand Preventable Harms and Socioeconomic Factors?
Rates for maternal morbidity and mortality are higher in the U.S. than in any other developed country—and many of the harms suffered by patients are preventable. In a multifactorial study, David L. Feldman, MD, MBA, FACS, Chief Medical Officer, The Doctors Company and TDC Group; Jacqueline Ross, PhD, RN, CPAN, Coding Director, Department of Patient Safety and Risk Management, The Doctors Company, and Shelise Valentine, RNC, MSN, Director of Clinical Education, Healthcare Risk Advisors, part of TDC Group, investigated postpartum claims to develop clinical recommendations to decrease the risks of postpartum morbidity and mortality.

Stay in the Know

Sign up for The Doctor’s Practice.

Our e-newsletter features timely articles, videos, and guides on a range of patient safety topics.

Subscribe